Publications from OUS - Section for lung oncology

150 publications found

1. Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, Slordahl K, Tamburstuen MV, Reseland JE, Syversen U (2006)
   Serotonin and fluoxetine modulate bone cell function in vitro
   J. Cell. Biochem., 98 (1), 139-151
   DOI 10.1002/jcb.20734
2. Helland A, Solberg S, Brustugun OT (2012)
   Incidence and Survival of Malignant Pleural Mesothelioma in Norway A Population-Based Study of 1686 Cases
   J. Thorac. Oncol., 7 (12), 1858-1861
   DOI 10.1097/JTO.0b013e318275b346
3. Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Brustugun OT, O'Connell DL, Yu XQ, Moller B (2016)
   Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage
   Int. J. Cancer, 138 (6), 1350-1360
   DOI 10.1002/ijc.29875
4. Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, Arraras JI, Morag O, Pompili C, Ioannidis G, Georgiou M, Navarra C, Chie WC, Johnson CD, Himpel A, Schulz C, Bohrer T, Janssens A, Kulis D, Bottomley A, EORTC Quality Life Grp EORTC Lung Canc Grp European Soc Thoracic Surg (2017)
   An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients
   Ann. Oncol., 28 (11), 2874-2881
   DOI 10.1093/annonc/mdx453
5. Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland A (2021)
   COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
   Front. Oncol., 11, 652535
   DOI 10.3389/fonc.2021.652535
6. Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fossa SD, Oldenburg J, Travis LB (2012)
   Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer
   J. Clin. Oncol., 30 (3), 300-307
   DOI 10.1200/JCO.2011.37.4025
7. Darabi H, Mccue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
   Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
   Am. J. Hum. Genet., 97 (1), 22-34
   DOI 10.1016/j.ajhg.2015.05.002
8. Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland A (2017)
   Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
   Dis. Markers, 2017, 3098542
   DOI 10.1155/2017/3098542
9. Halvorsen TO, Stokke K, Killingberg KT, Raj SX, Sorhaug S, Brustugun OT, Flotten O, Helbekkmo N, Hornslien K, Madebo T, Fluge S, Gronberg BH (2020)
   Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
   Acta Oncol., 59 (9), 1051-1057
   DOI 10.1080/0284186X.2020.1778179
10. Strand TE, Brunsvig PF, Johannessen DC, Sundstrom S, Wang M, Hornslien K, Bremnes RM, Stensvold A, Garpestad O, Norstein J (2011)
    POTENTIALLY CURATIVE RADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER IN NORWAY: A POPULATION-BASED STUDY OF SURVIVAL
    Int. J. Radiat. Oncol. Biol. Phys., 80 (1), 133-141
    DOI 10.1016/j.ijrobp.2010.01.050
11. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis MLH, Haakensen VD, Warnberg F, Naume B, Helland A, Borresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
    Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
    Genome Biol., 15 (8), 435
    DOI 10.1186/s13059-014-0435-x
12. Eide HA, Halvorsen AR, Sandhu V, Fane A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland A (2016)
    Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
    Clin. Transl. Immunol., 5, e109
    DOI 10.1038/cti.2016.65
13. Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
    Lung cancer: Improved prognosis presents capacity challenges
    Tidsskr. Nor. Laegeforen., 140 (5), 432-434
14. Courter D, Cao HB, Kwok S, Kong C, Banh A, Kuo PW, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT (2010)
    The RGD Domain of Human Osteopontin Promotes Tumor Growth and Metastasis through Activation of Survival Pathways
    PLoS One, 5 (3), e9633
    DOI 10.1371/journal.pone.0009633
15. Brustugun OT, Khattak AM, Tromborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland A (2014)
    BRAF-mutations in non-small cell lung cancer
    Lung Cancer, 84 (1), 36-38
    DOI 10.1016/j.lungcan.2014.01.023
16. Halvorsen AR, Bjaanaes M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Penalver JC, Cervera J, Mojarrieta JC, Lopez-Guerrero JA, Brustugun OT, Helland A (2016)
    A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
    Oncotarget, 7 (24), 37250-37259
    DOI 10.18632/oncotarget.9363
17. Stankovic B, Bjorhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Muller E, Hammarstrom C, Beraki K, Baekkevold ES, Woldbaek PR, Helland A, Brustugun OT, Oynebraten I, Corthay A (2019)
    Immune Cell Composition in Human Non-small Cell Lung Cancer
    Front. Immunol., 9, 3101
    DOI 10.3389/fimmu.2018.03101
18. Ojlert AK, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, Chee J, Helland A (2021)
    Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
    Mol. Oncol., 15 (11), 2958-2968
    DOI 10.1002/1878-0261.13082
19. Edvardsen H, Kristensen VN, Alnaes GIG, Bohn M, Erikstein B, Helland A, Borresen-Dale AL, Fossa SD (2007)
    Germline glutathione S-transferase variants in breast cancer: Relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy
    Int. J. Radiat. Oncol. Biol. Phys., 67 (4), 1163-1171
    DOI 10.1016/j.ijrobp.2006.11.009
20. Gronberg BH, Lund-Iversen M, Strom EH, Brustugun OT, Scott H (2013)
    Associations between TS, TTF-1, FR-alpha, FPGS, and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy
    J. Thorac. Oncol., 8 (10), 1255-1264
    DOI 10.1097/JTO.0b013e3182a406a3
21. Rogg LV (2015)
    Medical humanities companion, vol 4, Prognosis
    Tidsskr. Nor. Laegeforen., 135 (4), 358
    DOI 10.4045/tidsskr.14.1392
22. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland A (2018)
    Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
    Acta Oncol., 57 (9), 1225-1231
    DOI 10.1080/0284186X.2018.1465585
23. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanaes MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland A (2021)
    NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    J. Transl. Med., 19 (1), 232
    DOI 10.1186/s12967-021-02905-3
24. Turzer M, Brustugun OT, Helland A (2010)
    Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
    Case Rep. Oncol., 3 (2), 195-201
    DOI 10.1159/000317104
25. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland A, Brustugun OT (2012)
    Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations
    J. Thorac. Oncol., 7 (9), 1471-1473
    DOI 10.1097/JTO.0b013e3182614a9d
26. Arnesen MR, Knudtsen IS, Rekstad BL, Eilertsen K, Dale E, Bruheim K, Helland A, Londalen AM, Hellebust TP, Malinen E (2015)
    Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps
    Acta Oncol., 54 (9), 1607-1613
    DOI 10.3109/0284186X.2015.1061690
27. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland A, Naume B, Caldas C, Borresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
    Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
    Oncotarget, 8 (34), 57121-57133
    DOI 10.18632/oncotarget.19078
28. Ojlert AK, Nebdal D, Lund-Iversen M, Ellefsen RA, Brustugun OT, Gran JM, Halvorsen AR, Helland A (2021)
    Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
    Acta Oncol., 60 (2), 149-156
    DOI 10.1080/0284186X.2020.1854851
29. Haakensen VD, Lingjaerde OC, Luders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Borresen-Dale AL, Helland A (2011)
    Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
    BMC Med. Genomics, 4, 77
    DOI 10.1186/1755-8794-4-77
30. Potapenko IO, Luders T, Russnes HG, Helland A, Sorlie T, Kristensen VN, Nord S, Lingjaerde OC, Borresen-Dale AL, Haakensen VD (2015)
    Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
    Mol. Oncol., 9 (4), 861-876
    DOI 10.1016/j.molonc.2014.12.013
31. McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland A, Hirsch FR, Brustugun OT (2017)
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
    Lung Cancer, 103, 52-57
    DOI 10.1016/j.lungcan.2016.11.018
32. Stankovic B, Aamodt H, Bjorhovde HAK, Muller E, Hammarstrom C, Brustugun OT, Helland A, Oynebraten I, Corthay A (2020)
    The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
    Scand. J. Immunol., 92 (2), e12893
    DOI 10.1111/sji.12893
33. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schottle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansen S, Rauh D, Baessmann I et al. (2010)
    Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
    Sci. Transl. Med., 2 (62), 62ra93
    DOI 10.1126/scitranslmed.3001451
34. Bjaanaes MM, Halvorsen AR, Solberg S, Jorgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Rresen-Dale ALB, Brustugun OT, Helland A (2014)
    Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
    Int. J. Cancer, 135 (8), 1812-1821
    DOI 10.1002/ijc.28828
35. Halvorsen TO, Sundstrom S, Flotten O, Brustugun OT, Brunsvig P, Aasebo U, Bremnes RM, Kaasa S, Gronberg BH (2016)
    Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
    Acta Oncol., 55 (11), 1349-1354
    DOI 10.1080/0284186X.2016.1201216
36. Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland A, Hjelde HH, Jakobsen B, Moller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L (2019)
    Increase in curative treatment and survival of lung cancer in Norway 2001-2016
    Eur. J. Epidemiol., 34 (10), 951-955
    DOI 10.1007/s10654-019-00536-z
37. Damhuis RAM, Senan S, Khakwani A, Harden S, Helland A, Strand TE (2021)
    Age-related treatment patterns for stage I NSCLC in three European countries
    J. Geriatr. Oncol., 12 (8), 1214-1219
    DOI 10.1016/j.jgo.2021.05.005
38. Kamalakaran S, Kendall J, Zhao XY, Tang CL, Khan S, Ravi K, Auletta T, Riggs M, Wang Y, Helland A, Naume B, Dimitrova N, Boresen-Dale AL, Hicks J, Lucito R (2009)
    Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
    Nucleic Acids Res., 37 (12), e89
    DOI 10.1093/nar/gkp413
39. Choudhury S, Almendro V, Merino VF, Wu ZH, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M et al. (2013)
    Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27(+) Cell Population with Progenitor Characteristics
    Cell Stem Cell, 13 (1), 117-130
    DOI 10.1016/j.stem.2013.05.004
40. Berg AS, Londalen A, Brustugun OT (2015)
    Typical growth pattern in malignant pleural mesothelioma
    Tidsskr. Nor. Laegeforen., 135 (11), 1050
    DOI 10.4045/tidsskr.14.0480
41. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland A, Han JY, Aix SP, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L (2018)
    Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
    J. Thorac. Oncol., 13 (12), 1906-1918
    DOI 10.1016/j.jtho.2018.08.2027
42. Digernes I, Grovik E, Nilsen LB, Saxhaug C, Geier O, Reitan E, Saetre DO, Breivik B, Reese T, Jacobsen KD, Helland A, Emblem KE (2018)
    Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery
    Adv. Radiat. Oncol., 3 (4), 559-567
    DOI 10.1016/j.adro.2018.05.005
43. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G (2006)
    Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    Int. J. Cancer, 118 (11), 2877-2881
    DOI 10.1002/ijc.21709
44. Baumbusch LO, Helland A, Wang Y, Liestol K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Mitchell G, Fereday S, DeFazio A, Bowtell DDL, Kristensen GB, Lingjaerde OC, Borresen-Dale AL, Australian Ovarian Canc Study Grp (2013)
    High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
    PLoS One, 8 (1), e54356
    DOI 10.1371/journal.pone.0054356
45. Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SGF, Helgeland L, Flotten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM (2016)
    Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
    Ann. Oncol., 27 (2), 226-232
    DOI 10.1093/annonc/mdv560
46. Rogg L (2018)
    NO MAN'S LAND For those who did not die, who are no longer sick, nor are they healthy
    Tidsskr. Nor. Laegeforen., 138 (5), 483
47. Slordahl KS, Klotz D, Olsen JA, Skovlund E, Undseth C, Abildgaard HL, Braendengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
    Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
    Acta Oncol., 60 (7), 921-930
    DOI 10.1080/0284186X.2021.1918763
48. Waldeland E, Ramberg C, Arnesen MR, Helland A, Brustugun OT, Malinen E (2012)
    Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors
    Acta Oncol., 51 (5), 603-609
    DOI 10.3109/0284186X.2012.658115
49. George J, Lim JS, Jang SJ, Cun YP, Ozretic L, Kong G, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Muller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N et al. (2015)
    Comprehensive genomic profiles of small cell lung cancer
    Nature, 524 (7563), 47-53
    DOI 10.1038/nature14664
50. Brustugun OT, Sprauten M, Helland A (2017)
    Real-world data on nivolumab treatment of non-small cell lung cancer
    Acta Oncol., 56 (3), 438-440
    DOI 10.1080/0284186X.2016.1253865
51. Koch M, Hjermstad MJ, Tomaszewski K, Tomaszewska I, Hornslien K, Harle A, Arraras J, Morag O, Pompili C, Ioannidis G, Navarra C, Chie W, Johnson C, Bohrer T, Janssens A, Kulis D, Bottomley A, Schulz C, Zeman F, Koller M (2020)
    Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study
    J. Thorac. Dis., 12 (8), 4253-4261
    DOI 10.21037/jtd-20-1054
52. Knudtsen IS, Rodal J, Brustugun OT, Helland A, Skretting A, Malinen E (2011)
    Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study
    Acta Oncol., 50 (6), 889-896
    DOI 10.3109/0284186X.2011.583266
53. Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F (2014)
    GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
    Genome Biol., 15 (8), 442
    DOI 10.1186/s13059-014-0442-y
54. Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Alnaes GIG, Riis MLH, Helland A, Hautaniemi S, Lonning PE, Naume B, Borresen-Dale AL, Tost J, Kristensen VN (2017)
    DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
    Oncotarget, 8 (1), 1074-1082
    DOI 10.18632/oncotarget.13718
55. Eide IJZ, Helland A, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Gronberg BH, Brustugun OT (2020)
    Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Lung Cancer, 143, 27-35
    DOI 10.1016/j.lungcan.2020.03.009
56. Potapenko IO, Haakensen VD, Luders T, Helland A, Bukholm I, Sorlie T, Kristensen VN, Lingjaerde OC, Borresen-Dale AL (2010)
    Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
    Mol. Oncol., 4 (2), 98-118
    DOI 10.1016/j.molonc.2009.12.001
57. Fernandez-Cuesta L, Peifer M, Lu X, Sun RP, Ozretic L, Seidel D, Zander T, Leenders F, George J, Muller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmuller J, Nurnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland A, Solberg S, Lund-Iversen M et al. (2014)
    Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
    Nat. Commun., 5, 3518
    DOI 10.1038/ncomms4518
58. Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IRK, Luders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Borresen-Dale AL, Hovig E, Helland A (2016)
    Subtype-specific micro-RNA expression signatures in breast cancer progression
    Int. J. Cancer, 139 (5), 1117-1128
    DOI 10.1002/ijc.30142
59. Abravan A, Eide HA, Londalen AM, Helland A, Malinen E (2019)
    Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
    Mol. Imaging. Biol., 21 (2), 391-398
    DOI 10.1007/s11307-018-1226-7
60. Eide IJZ, Grut H, Helland A, Ekman S, Sorensen JB, Hansen KH, Gronberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
    Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
    Acta Oncol., 60 (12), 1565-1571
    DOI 10.1080/0284186X.2021.1973092
61. Thorsen L, Dahl AA, Skovlund E, Hornslien K, Fossa SD (2007)
    Effectiveness after 1 year of a short-term physical activity intervention on cardiorespiratory fitness in cancer patients
    J. Clin. Oncol., 25 (10), 1301-1302
    DOI 10.1200/JCO.2007.10.6682
62. Seidel D, Zander T, Heukamp LC, Peifer M, Bos M, Fernandez-Cuesta L, Leenders F, Lu X, Ansen S, Gardizi M, Nguyen C, Berg J, Russell P, Wainer Z, Schildhaus HU, Rogers TM, Solomon B, Pao W, Carter SL, Getz G, Hayes DN, Wilkerson MD, Thunnissen E, Travis WD, Perner S et al. (2013)
    A Genomics-Based Classification of Human Lung Tumors
    Sci. Transl. Med., 5 (209), 209ra153
    DOI 10.1126/scitranslmed.3006802
63. Brustugun OT (2015)
    A rapid development?
    Tidsskr. Nor. Laegeforen., 135 (5), 413-414
    DOI 10.4045/tidsskr.15.0208
64. Brustugun OT (2016)
    Stratification in advanced non-small cell lung cancer: precision medicine in practice
    Expert Rev. Precis. Med. Drug Dev., 1 (3), 279-287
    DOI 10.1080/23808993.2016.1176861
65. Bjaanaes MM, Sande EPS, Loe O, Ramberg C, Naess TM, Ottestad A, Rogg LV, Svestad JG, Haakensen VD (2021)
    Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
    Phys. Imag. Radiat. Oncol., 18, 51-54
    DOI 10.1016/j.phro.2021.04.003
66. Turzer M, Brustugun OT, Waldeland E, Helland A (2011)
    Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity
    Case Rep. Oncol., 4 (1), 25-34
    DOI 10.1159/000324113
67. Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Maelandsmo GM, Boye K (2012)
    Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
    BMC Cancer, 12, 333
    DOI 10.1186/1471-2407-12-333
68. Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland A (2016)
    EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
    Acta Oncol., 55 (2), 149-155
    DOI 10.3109/0284186X.2015.1062537
69. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, Giannone V, D'Amelio AM, Zhang PK, Mookerjee B, Johnson BE (2017)
    Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
    Lancet Oncol., 18 (10), 1307-1316
    DOI 10.1016/S1470-2045(17)30679-4
70. Grovik E, Yi D, Iv M, Tong E, Nilsen LB, Latysheva A, Saxhaug C, Jacobsen KD, Helland A, Emblem KE, Rubin DL, Zaharchuk G (2021)
    Handling missing MRI sequences in deep learning segmentation of brain metastases: a multicenter study
    npj Digit. Med., 4 (1), 33
    DOI 10.1038/s41746-021-00398-4
71. Sagerup CMT, Smastuen M, Johannesen TB, Helland A, Brustugun OT (2012)
    Increasing Age and Carcinoma Not Otherwise Specified A 20-Year Population Study of 40,118 Lung Cancer Patients
    J. Thorac. Oncol., 7 (1), 57-63
    DOI 10.1097/JTO.0b013e3182307f7e
72. Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland A, Alexeyev OA, Hallberg B, Palmer RH (2015)
    Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
    PLoS One, 10 (5), e0123542
    DOI 10.1371/journal.pone.0123542
73. Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Wielenga VT, Talman MLM, Brunner N, Borresen-Dale AL, Gromov P, Helland A, Kristensen VN, Gromova I (2016)
    Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
    OncoImmunology, 5 (12), e1248015
    DOI 10.1080/2162402X.2016.1248015
74. Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini S, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Muller K, Grafenstein L, Schulz C, Bottomley A et al. (2020)
    Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
    Lancet Oncol., 21 (5), 723-732
    DOI 10.1016/S1470-2045(20)30093-0
75. Helland A, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jorgensen L, Ariansen S, Brustugun OT (2011)
    EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery
    J. Thorac. Oncol., 6 (5), 947-950
    DOI 10.1097/JTO.0b013e31820db209
76. Brustugun OT, Moller B, Helland A (2014)
    Years of life lost as a measure of cancer burden on a national level
    Br. J. Cancer, 111 (5), 1014-1020
    DOI 10.1038/bjc.2014.364
77. Nyman J, Hallqvist A, Lund JA, Brustugun OT, Bergman B, Bergstrom P, Friesland S, Lewensohn R, Holmberg E, Lax I (2016)
    SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
    Radiother. Oncol., 121 (1), 1-8
    DOI 10.1016/j.radonc.2016.08.015
78. Nygard S, Lingjaerde OC, Caldas C, Hovig E, Borresen-Dale AL, Helland A, Haakensen VD (2019)
    PathTracer: High-sensitivity detection of differential pathway activity in tumours
    Sci Rep, 9, 16332
    DOI 10.1038/s41598-019-52529-3
79. Lehtio J, Arslan T, Siavelis I, Pan YB, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jonsson M, Brunnstrom H, Brustugun OT, Purohit KP, Cunningham R, Asl HF, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevskaz M, Hansen CG, Haakensen VD, Helland A, Tamborero D, Johansson HJ et al. (2021)
    Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms
    Nat. Cancer, 2 (11), 1224-+
    DOI 10.1038/s43018-021-00259-9
80. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SMF, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws ALF, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HYS, Nishikawa A, Niwa Y et al. (2009)
    TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies
    Lancet Oncol., 10 (8), 772-784
    DOI 10.1016/S1470-2045(09)70187-1
81. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Munoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis J, Gascon P, Gonen M, Michor F, Polyak K (2014)
    Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
    Cell Reports, 6 (3), 514-527
    DOI 10.1016/j.celrep.2013.12.041
82. Gronberg BH, Halvorsen TO, Flotten O, Brustugun OT, Brunsvig PF, Aasebo U, Bremnes RM, Tollali T, Hornslien K, Aksnessaether BY, Liaaen ED, Sundstrom S, Norwegian Lung Canc Study Grp (2016)
    Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
    Acta Oncol., 55 (5), 591-597
    DOI 10.3109/0284186X.2015.1092584
83. Helland A (2018)
    Groundbreaking basic research
    Tidsskr. Nor. Laegeforen., 138 (20), 1905
84. Yi D, Grovik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland A, Zaharchuk G, Rubin D (2021)
    MRI pulse sequence integration for deep-learning-based brain metastases segmentation
    Med. Phys., 48 (10), 6020-6035
    DOI 10.1002/mp.15136
85. Thorsen L, Nystad W, Stigum H, Hjermstad M, Oldervoll L, Martinsen EW, Hornslien K, Stromme SB, Dahl AA, Fossa SD (2006)
    Cardiorespiratory fitness in relation to self-reported physical function in cancer patients after chemotherapy
    J. Sports Med. Phys. Fit., 46 (1), 122-127
86. Nordgard O, Singh G, Solberg S, Jorgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland A (2013)
    Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
    PLoS One, 8 (5), e62153
    DOI 10.1371/journal.pone.0062153
87. Bjaanaes MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jorgensen L, Kure E, Edvardsen H, Borresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland A (2016)
    Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
    Mol. Oncol., 10 (2), 330-343
    DOI 10.1016/j.molonc.2015.10.021
88. George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Muller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun RP, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmuller J, Becker C, Nurnberg P, Achter V, Lang U, Schneider PM et al. (2018)
    Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
    Nat. Commun., 9, 1048
    DOI 10.1038/s41467-018-03099-x
89. Berg J, Ramberg C, Haugstvedt JOS, Bengtson MB, Gabrielsen AM, Brustugun OT, Halvorsen AR, Helland A (2021)
    Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
    Front. Oncol., 11, 674731
    DOI 10.3389/fonc.2021.674731
90. Kleveland A, Syversen U, Slordahl K, Waldum HL (2001)
    Hypergastrinemia as a cause of chromogranin A increase in blood in patients suspected to have neuroendocrine tumor
    Digestion, 64 (2), 71-74
    DOI 10.1159/000048842
91. Nordlund MS, Stieber P, Brustugun OT, Warren DJ, Paus E (2012)
    Characteristics and clinical validity of two immunoassays for ProGRP
    Tumor Biol., 33 (4), 1105-1113
    DOI 10.1007/s13277-012-0351-1
92. Lund-Iversen M, Groholt KK, Helland A, Borgen E, Brustugun OT (2015)
    NUT expression in primary lung tumours
    Diagn. Pathol., 10, 156
    DOI 10.1186/s13000-015-0395-9
93. Helland A, Brustugun OT, Nakken S, Halvorsen AR, Donnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jorgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
    High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
    Int. J. Cancer, 141 (1), 184-190
    DOI 10.1002/ijc.30726
94. Digernes I, Nilsen LB, Grovik E, Bjornerud A, Lovland G, Vik-Mo E, Meling TR, Saxhaug C, Helland A, Jacobsen KD, Geier O, Emblem KE (2020)
    Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI
    Phys. Med. Biol., 65 (22), 225020
    DOI 10.1088/1361-6560/abb71a
95. Haakensen VD, Bjoro T, Luders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Borresen-Dale AL, Helland A (2011)
    Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
    BMC Cancer, 11, 332
    DOI 10.1186/1471-2407-11-332
96. Brustugun OT (2015)
    Hypoxia as a Cause of Treatment Failure in Non-Small Cell Carcinoma of the Lung
    Semin. Radiat. Oncol., 25 (2), 87-92
    DOI 10.1016/j.semradonc.2014.11.006
97. Halvorsen TO, Herje M, Levin N, Bremnes RM, Brustugun OT, Flotten O, Kaasa S, Sundstrom S, Gronberg BH (2016)
    Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
    Lung Cancer, 102, 9-14
    DOI 10.1016/j.lungcan.2016.10.003
98. Frafjord A, Skarshaug R, Hammarstrom C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland A, Brustugun OT, Oynebraten I, Corthay A (2020)
    Antibody combinations for optimized staining of macrophages in human lung tumours
    Scand. J. Immunol., 92 (1), e12889
    DOI 10.1111/sji.12889
99. Rogg L, Aasland OG, Graugaard PK, Loge JH (2010)
    Direct communication, the unquestionable ideal? Oncologists' accounts of communication of bleak prognoses
    Psycho-Oncol., 19 (11), 1221-1228
    DOI 10.1002/pon.1691
100. Saldova R, Shehni AA, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Borresen-Dale AL, Rudd PM (2014)
     Association of N-Glycosylation with Breast Carcinoma and Systemic Features Using High-Resolution Quantitative UPLC
     J. Proteome Res., 13 (5), 2314-2327
     DOI 10.1021/pr401092y
101. Rud AK, Boye K, Fodstad O, Juell S, Jorgensen LH, Solberg S, Helland A, Brustugun OT, Maelandsmo GM (2016)
     Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
     Diagn. Pathol., 11, 50
     DOI 10.1186/s13000-016-0504-4
102. Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland A, Sorlie T, Haakensen VD (2019)
     A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
     J. Mammary Gland Biol. Neoplasia, 24 (2), 163-175
     DOI 10.1007/s10911-018-09423-x
103. Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
     Immunotherapy in malignant pleural mesothelioma
     Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169
104. Lyng H, Lando M, Brovig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
     GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
     Genome Biol., 9 (5), R86
     DOI 10.1186/gb-2008-9-5-r86
105. Brustugun OT, Helland A (2014)
     Rapid reduction in the incidence of cancer of unknown primary. A population-based study
     Acta Oncol., 53 (1), 134-137
     DOI 10.3109/0284186X.2013.783230
106. Helland A (2015)
     Cancer stem cells
     Tidsskr. Nor. Laegeforen., 135 (8), 783
     DOI 10.4045/tidsskr.15.0031
107. Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydoy M, Tandstad T, Wilsgaard T, Fossa SD, Oldenburg J, Bremnes RM, Haugnes HS (2018)
     Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors
     Acta Oncol., 57 (10), 1392-1400
     DOI 10.1080/0284186X.2018.1473641
108. Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersall P, Persson GF, Josipovic M, Khalil AA, Moeller DS, Nyman J, Drugge N, Bergstrom P, Olofsson J, Rogg LV, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Loden B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R (2021)
     The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy
     J. Thorac. Oncol., 16 (7), 1200-1210
     DOI 10.1016/j.jtho.2021.03.019
109. Thorsen L, Skovlund E, Stromme SB, Hornslien K, Dahl AA, Fossa SD (2005)
     Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy
     J. Clin. Oncol., 23 (10), 2378-2388
     DOI 10.1200/JCO.2005.04.106
110. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun RP, Zander T, Menon R, Koker M, Dahmen I, Muller C, Di Cerbo V, Schildhaus HU, Altmuller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Bohm D, Ansen S, Gabler F, Wilkening I et al. (2012)
     Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
     Nature Genet., 44 (10), 1104-+
     DOI 10.1038/ng.2396
111. Eide HA, Halvorsen AR, Bjaanaes MM, Piri H, Holm R, Solberg S, Jorgensen L, Brustugun OT, Kiserud CE, Helland A (2016)
     The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma-differences in histological subtypes
     BMC Cancer, 16, 71
     DOI 10.1186/s12885-016-2104-9
112. Vandraas KF, Torfoss D, Berstad AE, Horndalsveen H, Turowski G (2017)
     Cancer patient in the 50s with troublesome palpitations
     Tidsskr. Nor. Laegeforen., 137 (16), 1210-1213
113. Gronberg BH, Killingberg KT, Flotten O, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO (2021)
     High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
     Lancet Oncol., 22 (3), 321-331
114. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sorlie T, Warnberg F, Haakensen VD, Helland A, Naume B, Perou CM, Haussler D, Troyanskaya OG, Borresen-Dale AL (2012)
     Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
     Proc. Natl. Acad. Sci. U. S. A., 109 (8), 2802-2807
     DOI 10.1073/pnas.1108781108
115. Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT (2015)
     Stromal CD8(+) T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
     Clin. Cancer Res., 21 (11), 2635-2643
     DOI 10.1158/1078-0432.CCR-14-1905
116. Manegold C, Dingemans AMC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Perol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JCH et al. (2017)
     The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
     J. Thorac. Oncol., 12 (2), 194-207
     DOI 10.1016/j.jtho.2016.10.003
117. Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jorgensen LH, Brustugun OT, Kure EH, Helland A (2020)
     Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
     Int. J. Cancer, 147 (10), 2957-2966
     DOI 10.1002/ijc.33121
118. Berg A, Brustugun OT, Lund-Iversen M, Helland A (2011)
     Palmar Bullous Blistering Induced by Erlotinib
     J. Thorac. Oncol., 6 (5), 954
     DOI 10.1097/JTO.0b013e318211136b
119. Halvorsen AR, Helland A, Fleischer T, Haug KM, Alnaes GIG, Nebdal D, Syljuasen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Borresen-Dale AL, Kristensen V, Edvardsen H (2014)
     Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
     Int. J. Cancer, 135 (9), 2085-2095
     DOI 10.1002/ijc.28862
120. Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen YY, Stutz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R et al. (2017)
     Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
     Nature Genet., 49 (1), 65-74
     DOI 10.1038/ng.3722
121. Umu SU, Langseth H, Keller A, Meese E, Helland A, Lyle R, Rounge TB (2020)
     A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
     Mol. Oncol., 14 (2), 235-247
     DOI 10.1002/1878-0261.12620
122. Rogg L, Loge JH, Aasland OG, Graugaard PK (2009)
     Physicians' attitudes towards disclosure of prognostic information A survey among a representative cross-section of 1605 Norwegian physicians
     Patient Educ. Couns., 77 (2), 242-247
     DOI 10.1016/j.pec.2009.03.007
123. Sprauten M, Brydoy M, Haugnes HS, Cvancarova M, Bjoro T, Bjerner J, Fossa SD, Oldenburg J (2014)
     Longitudinal Serum Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone Levels in a Population-Based Sample of Long-Term Testicular Cancer Survivors
     J. Clin. Oncol., 32 (6), 571-578
     DOI 10.1200/JCO.2013.51.2715
124. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Borresen-Dale AL, Brustugun OT, Helland A (2016)
     TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
     Front. Genet., 7, 85
     DOI 10.3389/fgene.2016.00085
125. Shao BR, Bjaanaes MM, Helland A, Schutte C, Conrad T (2019)
     EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
     PLoS One, 14 (1), e0204186
     DOI 10.1371/journal.pone.0204186
126. Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung JY, Appenzeller C, Sun ZW, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, Bar J (2021)
     Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage- SCLC: Results From the Phase 3 MERU Study
     J. Thorac. Oncol., 16 (9), 1570-1581
     DOI 10.1016/j.jtho.2021.03.012
127. Helland A, Johnsen H, Froyland C, Landmark HBK, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, Ottestad LO, Rodningen OK, Sherlock G, Borresen-Dale AL (2006)
     Radiation-induced effects on gene expression: An in vivo study on breast cancer
     Radiother. Oncol., 80 (2), 230-235
     DOI 10.1016/j.radonc.2006.07.007
128. Rud AK, Borgen E, Maelandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland A, Jorgensen L, Brustugun OT, Fodstad O, Boye K (2013)
     Clinical significance of disseminated tumour cells in non-small cell lung cancer
     Br. J. Cancer, 109 (5), 1264-1270
     DOI 10.1038/bjc.2013.450
129. Helland A (2015)
     Gene jockeys Life science and the rise of biotech enterprise.
     Tidsskr. Nor. Laegeforen., 135 (4), 356
     DOI 10.4045/tidsskr.14.1367
130. Brustugun OT, Gronberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland A, Moller B, Nilssen Y, Strand TE, Solberg SK (2018)
     Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
     Lung Cancer, 122, 138-145
     DOI 10.1016/j.lungcan.2018.06.003
131. Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland A, Hochmair M, Perol M, Bent-Ennakhil N, Kruhl C, Novello S (2021)
     Real-world treatment outcomes with brigatinib in patients with pretreated ALK plus metastatic non-small cell lung cancer
     Lung Cancer, 157, 9-16
     DOI 10.1016/j.lungcan.2021.05.017
132. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL (2005)
     PIK3CA Mutations in Advanced Ovarian Carcinomas
     Hum. Mutat., 25 (3)
     DOI 10.1002/humu.9316
133. Flotten O, Gronberg BH, Bremnes R, Amundsen T, Sundstrom S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebo U, von Plessen C (2012)
     Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
     Br. J. Cancer, 107 (3), 442-447
     DOI 10.1038/bjc.2012.284
134. Sprauten M, Haugnes HS, Brydoy M, Kiserud C, Tandstad T, Bjoro T, Bjerner J, Cvancarova M, Fossa SD, Oldenburg J (2015)
     Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors
     Ann. Oncol., 26 (10), 2133-2140
     DOI 10.1093/annonc/mdv328
135. Halvorsen AR, Helland A, Gromov P, Wielenga VT, Talman MLM, Brunner N, Sandhu V, Borresen-Dale AL, Gromova I, Haakensen VD (2017)
     Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
     Mol. Oncol., 11 (2), 220-234
     DOI 10.1002/1878-0261.12025
136. Halvorsen AR, Haugen MH, Ojlert AK, Lund-Iversen M, Jorgensen L, Solberg S, Maelandsmo GM, Brustugun OT, Helland A (2020)
     Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
     Front. Oncol., 10, 590755
     DOI 10.3389/fonc.2020.590755
137. Hammerman PS, Sos ML, Ramos AH, Xu CX, Dutt A, Zhou WJ, Brace LE, Woods BA, Lin WC, Zhang JM, Deng XM, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F et al. (2011)
     Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer
     Cancer Discov., 1 (1), 78-89
     DOI 10.1158/2159-8274.CD-11-0005
138. Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schottle J, Ullrich RT, Altmuller J, Becker C, Nurnberg P, Seidel H, Bohm D, Goke F, Ansen S, Russell PA, Wright GM, Wainer Z et al. (2015)
     Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
     Genome Biol., 16, 7
     DOI 10.1186/s13059-014-0558-0
139. Hjelle LV, Bremnes RM, Gundersenc POM, Sprauten M, Brydoy M, Tandstad T, Wilsgaard T, Fossa SD, Oldenburg J, Haugnes HS (2016)
     Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors
     Urol. Oncol.-Semin. Orig. Investig., 34 (11)
     DOI 10.1016/j.urolonc.2016.06.012
140. Abravan A, Eide HA, Helland A, Malinen E (2020)
     Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
     Clin. Transl. Radiat. Oncol., 22, 15-21
     DOI 10.1016/j.ctro.2020.02.005
141. Haakensen VD, Biong M, Lingjaerde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Luders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Borresen-Dale AL, Helland A (2010)
     Expression levels of uridine 5 '-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
     Breast Cancer Res., 12 (4), R65
     DOI 10.1186/bcr2632
142. Sagerup CMT, Nymoen DA, Halvorsen AR, Lund-Iversen M, Helland A, Brustugun OT (2014)
     Human papilloma virus detection and typing in 334 lung cancer patients
     Acta Oncol., 53 (7), 952-957
     DOI 10.3109/0284186X.2013.879608
143. Varghese M, Nymoen HG, Saxhaug C, Krossnes B, Hosainey SAM, Meling TR, Brandal P (2016)
     Symptomatic spinal metastasis from intracranial glioblastoma multiforme - Two illustrative cases and a review of the literature
     Acta Oncol., 55 (9-10), 1236-1238
     DOI 10.3109/0284186X.2016.1161824
144. Dork T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova N, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL et al. (2019)
     Two truncating variants in FANCC and breast cancer risk
     Sci Rep, 9, 12524
     DOI 10.1038/s41598-019-48804-y
145. Bjaanaes MM, Nilsen G, Halvorsen AR, Russnes HG, Solberg S, Jorgensen L, Brustugun OT, Lingjaerde OC, Helland A (2021)
     Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
     BMC Cancer, 21 (1), 1089
     DOI 10.1186/s12885-021-08811-7
146. Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S (2009)
     Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: Results from a randomised multicentre trial
     Radiother. Oncol., 91 (2), 261-266
     DOI 10.1016/j.radonc.2009.02.014
147. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Maelandsmo GM (2013)
     Osteopontin is a prognostic biomarker in non-small cell lung cancer
     BMC Cancer, 13, 540
     DOI 10.1186/1471-2407-13-540
148. Helland A (2015)
     Viruses and human cancer
     Tidsskr. Nor. Laegeforen., 135 (9), 874
     DOI 10.4045/tidsskr.15.0167
149. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Borresen-Dale AL, Helland A, Markowetz F, Russnes HG (2018)
     Intratumor heterogeneity defines treatment-resistant HER2+breast tumors
     Mol. Oncol., 12 (11), 1838-1855
     DOI 10.1002/1878-0261.12375
150. Eide HA, Knudtsen IS, Sandhu V, Londalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland A (2018)
     Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
     Adv. Radiat. Oncol., 3 (2), 130-138
     DOI 10.1016/j.adro.2017.12.007